Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian CancersMarch 30th 2023
Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian CancerMarch 30th 2023
Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian CancerMarch 29th 2023
Lindsay K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.
Dr Westin on Outcomes of the SOLAR Trial in RAS-Mutant Gynecological MalignancesMarch 28th 2023
Shannon N. Westin, MD, MPH, FACOG, discusses the outcomes of the phase 1b SOLAR trial, which examined olaparib with selumetinib in patients with RAS-mutant gynecologic malignancies and other solid tumors.
Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian CancerMarch 28th 2023
Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial CancerMarch 28th 2023
Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial CancerMarch 28th 2023
Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.
Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian CancerMarch 28th 2023
Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.
Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal ResectionMarch 27th 2023
Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial CancerMarch 27th 2023
The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.
Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian CancerMarch 27th 2023
Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
Tolerability Hinders Adavosertib Activity in Recurrent or Persistent Uterine Serous CarcinomaMarch 27th 2023
Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.
Durvalumab Plus Tremelimumab and Hypofractionated Radiotherapy Shows Early Promise in Gynecologic Cancers
The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian CancerMarch 27th 2023
Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial CancerMarch 27th 2023
The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.
Post-Hoc Analysis Shows PFS Benefit of Maintenance Niraparib Not Affected by Dose Modifications in Ovarian CancerMarch 27th 2023
The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.
Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer
Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.
Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for LymphedemaMarch 26th 2023
The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.